Biotech insider buying
Query: biotech insider buying · data as of 2026-10-09
Biotech insider-buying screen refreshed: 31 US-listed biotech names with net open-market insider buying over the last 90 days, ranked by net buy as % of effective float (Braveheart Bio, Scribe Therapeutics, MapLight lead), plus a secondary table of the largest individual insider buys by dollar value (Baker Bros./Kodiak, Catalyst4/MapLight, Forbion/Braveheart). New qualitative comments and a market-context narrative applied.
US-listed biotech insiders are net buyers at 31 names over the last 90 days. Ranked by net purchases as a share of effective float, fresh clinical-stage IPOs (Braveheart Bio, Scribe Therapeutics, MapLight) show the heaviest insider conviction, while Kodiak Sciences and AbCellera combine large absolute buys with strong price momentum.
Biotech Insider Buying — Net Buyers, Last 90 Days
| Symbol | Company | Biotech Theme / Industry | Market Cap | Last Price | 1D Return | 1M Return | 6M Return | % From 150D SMA | Momentum Potential | Days Since Earnings | Net Shares Bought (90d) | Net $ Bought (90d) | Net Buy % of Float | Distinct Insiders | Insiders (net shares) | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BRVE | Braveheart Bio, Inc. Common Stock | Biopharma Drug Discovery Platforms | 1.803e+09 | 20.02 | 4.87% | -26.53% | — | — | — | 30 | 8.835e+06 | 1.59e+08 | 69.45% | 10 | — | Forbion, Orbimed, AH Bio and CEO Travis Murdoch all stepped up around the IPO — a deep bench of specialist crossover funds clustering in the same name signals conviction on the lead asset, though the tiny public float makes the % of float figure unusually large. |
| SCTX | Scribe Therapeutics Inc. | Biopharma Drug Discovery Platforms | 4.008e+08 | 21.17 | 10.09% | -28.16% | — | — | — | 36 | 4.73e+06 | 7.134e+07 | 68.66% | 6 | — | Gene-editing platform play whose insider buying came from founders and early backers, not open-market opportunism. The low float amplifies this reading; watch for thin liquidity to exaggerate moves either direction. |
| MPLT | MapLight Therapeutics, Inc. - Common Stock | Neurology & Rare Diseases | 4.907e+08 | 8.83 | -3.50% | -35.94% | -66.97% | -60.63% | 3.3 | 56 | 5.625e+06 | 6.554e+07 | 35.04% | 2 | — | CNS pipeline name backed by Catalyst4 and a director. Insider accumulation alongside a depressed share price can mark a capitulation-style bottom, but the science still hinges on clinical readouts rather than financing. |
| ETRA | Electra Therapeutics, Inc. - Common stock | Biotechnology | 5.674e+08 | 9.04 | -1.09% | — | — | — | — | — | 2.667e+06 | 4e+07 | 9.16% | 2 | — | Carl Gordon of Orbimed and a co-investor bought in a paired block shortly after listing — classic crossover-fund seed interest that usually implies a long lock-in horizon rather than a trade. |
| KOD | Kodiak Sciences Inc - Common Stock | Autoimmune & Immunology Therapies | 6.277e+09 | 99.87 | 5.95% | 203.83% | 131.66% | 142.87% | 65.5 | 56 | 1.942e+06 | 1.57e+08 | 5.27% | 1 | — | Baker Bros. built a large position into a stock already up sharply on the year — a rare case of a deep-pocketed specialist chasing strength rather than catching a falling knife. Retinal-disease data flow is the swing factor. |
| CBIO | Crescent Biopharma, Inc. - Common Stock | Oncology Therapeutics | 5.539e+08 | 14.91 | 5.59% | -23.38% | -17.94% | -13.73% | 3.5 | 71 | 8.534e+05 | 1.238e+07 | 3.16% | 1 | — | Fairmount Funds took an oncology position post-IPO. With modest cash and a small float, the sponsor's follow-on capacity matters as much as the initial buy for runway. |
| APMD | Apnimed, Inc. | Biopharma Drug Discovery Platforms | 7.71e+08 | 18.52 | 1.65% | -30.90% | — | — | — | 30 | 3.25e+05 | 5.2e+06 | 1.59% | 2 | Morningside Venture Investments Ltd (10% Owner): 312,500; SEKHRI PAUL J (Director): 12,500 | Morningside plus a director bought into this sleep-apnea biotech. The accumulation suggests insider confidence in the late-stage program even as the shares trade well below issue pricing. |
| LTGO | Latigo Biotherapeutics, Inc. Common Stock | Autoimmune & Immunology Therapies | 1.061e+09 | 16 | 8.18% | -25.72% | — | — | — | 35 | 2.8e+05 | 5.04e+06 | 1.29% | 2 | — | Foresite Capital and a director both added — a specialist-venture duo that typically leans on a defined catalyst window rather than momentum. Small clinical-stage risk remains binary. |
| IMTX | Immatics N.V. - Ordinary Shares | Oncology Therapeutics | 1.131e+09 | 7.43 | 0.81% | -15.09% | -28.76% | -23.81% | 27.9 | 52 | 8.631e+05 | 7.5e+06 | 1.23% | 1 | — | Perceptive Advisors, a director, bought into the cell-therapy oncology platform. Notable that the buyer sits on the board — alignment with the pivotal program's timing. |
| ALMS | Alumis Inc. - Common Stock | Autoimmune & Immunology Therapies | 9.268e+08 | 7.16 | 2.73% | -27.68% | -68.47% | -66.83% | 8.8 | 56 | 9.867e+05 | 1.073e+07 | 1.02% | 1 | AKKARAJU SRINIVAS (Director): 986,721 | A single large director purchase from an existing backer; the size dwarfs typical director grants and reads as a statement of confidence ahead of the company's immunology readouts. |
| INBX | Inhibrx Biosciences, Inc. - Common Stock | Oncology Therapeutics | 1.398e+09 | 95.01 | 2.43% | -14.73% | 52.38% | -0.71% | 83 | 56 | 5.25e+04 | 5.498e+06 | 0.61% | 3 | — | CEO Mark Lappe led a management-and-director cluster buy in this oncology antibody name. Insider buying by a sitting CEO after a period of share weakness is one of the more meaningful signals in biotech. |
| RLMD | Relmada Therapeutics, Inc. - Common Stock | Oncology Therapeutics | 3.616e+08 | 3.39 | 6.94% | -16.71% | -53.50% | -42.17% | 19.8 | 63 | 4e+05 | 1.672e+06 | 0.48% | 2 | — | Chemotherapy-support asset with concentrated small-float ownership; the buy is more about a coiled capital structure than broad institutional sponsorship. |
| PBLS | Parabilis Medicines, Inc. - Common Stock | Biopharma Drug Discovery Platforms | 3.395e+09 | 27.48 | -2.17% | -24.34% | — | — | — | 57 | 2.446e+05 | 6.92e+06 | 0.30% | 1 | — | RA Capital, a top-tier specialist, anchored this position. Sponsors of this caliber typically underwrite to a specific value-inflection event, so the buy is a vote on the pipeline rather than the tape. |
| KURA | Kura Oncology, Inc. - Common Stock | Oncology Therapeutics | 9.43e+08 | 10.6 | 0.76% | -8.38% | 20.18% | 4.94% | 13.9 | 57 | 2e+05 | 2.351e+06 | 0.28% | 1 | — | CEO Troy Wilson bought in a name that has been a repeat insider-buy candidate — sustained open-market accumulation by the top executive is a durable alignment signal for a small-cap oncology story. |
| EIKN | Eikon Therapeutics, Inc. - Common Stock | Oncology Therapeutics | 4.046e+08 | 7.47 | -0.40% | -18.89% | -17.00% | -26.69% | 31.7 | 56 | 8.92e+04 | 1.031e+06 | 0.27% | 1 | — | Column Group, a life-science-focused fund, added to this oncology platform. The modest dollar size reflects a small position, but the specialist sponsorship is the point. |
| RGNX | REGENXBIO Inc. - Common Stock | Biopharma Drug Discovery Platforms | 5.327e+08 | 8.07 | -0.25% | -5.72% | -8.30% | -11.25% | 38.8 | 64 | 1.026e+05 | 9.494e+05 | 0.18% | 1 | — | A director's purchase in a gene-therapy name trading near multi-year lows — value-style insider interest, though the sector's funding environment remains the dominant risk. |
| ABCL | AbCellera Biologics Inc. - Common Shares | Biopharma Drug Discovery Platforms | 4.065e+09 | 12.545 | 4.37% | 19.93% | 254.38% | 77.37% | 37 | 64 | 1.472e+05 | 1.546e+06 | 0.07% | 3 | Hayden Michael R: 100,000; Booth Andrew (Chief Financial Officer): 37,200; Montalbano John S.: 10,000 | AbCellera shows the largest market cap among biotech insider buyers and a director bought in — notable given the shares have been among the strongest performers in the group, i.e. insiders adding to a winner. |
| XENE | Xenon Pharmaceuticals Inc. - Common Shares | Neurology & Rare Diseases | 3.529e+09 | 36.44 | 0.77% | -38.03% | -37.60% | -35.41% | 3 | 63 | 4.5e+04 | 1.681e+06 | 0.05% | 2 | — | CEO and CFO both bought in a coordinated pair, and it comes after a sharp drawdown — a high-signal management-cluster buy for an epilepsy-focused pipeline. |
| DMRA | Damora Therapeutics, Inc. - Common Stock | Neurology & Rare Diseases | 1.301e+09 | 21.08 | 2.53% | -21.46% | -18.36% | -18.24% | 75.5 | 59 | 1.25e+04 | 2.529e+05 | 0.03% | 1 | — | Only the CEO bought, but in a recent IPO where float is thin the absolute size still stands out. Single-buyer reads are weaker than clusters, so treat with more caution. |
| COO | The Cooper Companies, Inc. | Autoimmune & Immunology Therapies | 1.034e+10 | 54.37 | 0.13% | 0.37% | -21.95% | -18.92% | 11.8 | 29 | 3.47e+04 | 1.88e+06 | 0.02% | 3 | — | A vision-care medical device name rather than a pure drug developer; several directors bought in a name that has lagged, a case of insider support for a consumer-facing contact-lens cycle. |
| ANNX | Annexon, Inc. - common stock | Autoimmune & Immunology Therapies | 7.621e+08 | 4.02 | 0.50% | -2.90% | -31.28% | -23.23% | 11.9 | 58 | 2.606e+04 | 9.983e+04 | 0.02% | 1 | Love Douglas (PRESIDENT AND CEO): 26,065 | CEO Douglas Love bought into a complement-therapy name near its lows. Keep in mind the dollar size is small relative to the float, so the conviction signal is weaker than the headline list position implies. |
| NAMS | NewAmsterdam Pharma Company N.V. - Ordinary Shares | Autoimmune & Immunology Therapies | 2.522e+09 | 21.575 | 1.48% | -1.30% | -37.93% | -27.83% | 15.6 | 65 | 1e+04 | 2.265e+05 | 0.01% | 1 | — | CEO Michael Davidson bought in a cardiometabolic/obesity-adjacent name — one of the only obesity-linked insiders on the list, and a space where strategic interest remains intense. |
| IONS | Ionis Pharmaceuticals, Inc. - Common Stock | Neurology & Rare Diseases | 7.525e+09 | 45.28 | 4.57% | -18.63% | -39.76% | -31.02% | 1.9 | 72 | 2e+04 | 1.059e+06 | 0.01% | 1 | — | A small director-led purchase layered onto a stock already under pressure from competitive RNA news. Note Michael Hayden appears as a buyer across multiple biotechs, so treat the signal as portfolio-wide rather than name-specific. |
| ASND | Ascendis Pharma A/S | Neurology & Rare Diseases | 1.508e+10 | 229.23 | 2.94% | -12.25% | -4.20% | -4.80% | 58.7 | 57 | 2,000 | 4.927e+05 | 0.00% | 1 | BIENAIME JEAN JACQUES (Director): 2,000 | Director Jean-Jacques Bienaimé bought a modest block in this rare-disease name; at this market cap the position size is more symbolic than a conviction bet. |
| TYRA | Tyra Biosciences, Inc. - Common Stock | Oncology Therapeutics | 1.371e+09 | 19.94 | -0.15% | -15.29% | -47.15% | -34.79% | 3.4 | 65 | 971.8943 | 2e+04 | 0.00% | 1 | — | A token director purchase in an FGFR-focused oncology name — minimal dollar value means the signal is weak relative to the float-based ranking. |
| INDV | Indivior Pharmaceuticals, Inc. | Neurology & Rare Diseases | 4.229e+09 | 35.83 | 1.07% | 3.82% | 17.32% | -1.13% | 17.2 | 67 | 3,000 | 1.08e+05 | 0.00% | 1 | — | Accounting-officer buy of a small block; non-executive purchases at this size are low-signal. |
| PFE | Pfizer, Inc. | Oncology Therapeutics, Pharmaceuticals | 1.612e+11 | 28.28 | 1.65% | 2.28% | 8.65% | 8.22% | 46 | 66 | 1.149e+05 | 2.96e+06 | 0.00% | 3 | — | Three distinct insiders at Pfizer bought small blocks. At mega-cap scale the % of float is negligible, but clustered insider buying at a large-cap pharma after a long underperformance period is a sentiment marker worth noting. |
| PGEN | Precigen, Inc. - Common Stock | Biopharma Drug Discovery Platforms, Oncology Therapeutics | 2.796e+09 | 7.81 | 2.76% | 16.92% | 87.74% | 46.24% | 64.2 | 65 | 3,411 | 2.466e+04 | 0.00% | 1 | — | A director's small buy in a gene-therapy name that has rallied hard; the position is minor relative to the move already made. |
| PODD | Insulet Corporation | Autoimmune & Immunology Therapies | 9.382e+09 | 135.28 | 0.60% | 0.45% | -31.31% | -17.76% | 18.5 | 65 | 1,100 | 1.622e+05 | 0.00% | 1 | — | CEO Ashley McEvoy bought a small block in this diabetes-device name. Minimal dollar size; more of a routine alignment buy than a strong signal. |
| DYN | Dyne Therapeutics, Inc. - Common Stock | Neurology & Rare Diseases | 3.107e+09 | 16.64 | 1.65% | -9.66% | -10.92% | -17.98% | 42.4 | 71 | 2,500 | 4e+04 | 0.00% | 1 | — | A director bought a small position in this muscle-disease biotech. With the tiny dollar value the float-based signal is muted. |
| AZN | AstraZeneca PLC | Oncology Therapeutics | 2.469e+11 | 159.2 | 0.26% | -0.28% | -20.72% | -10.73% | 15.1 | 74 | 20.233 | 3,249 | 0.00% | 1 | — | A lone insider buy of ~20 shares in a mega-cap ADR — economically immaterial; included for completeness but carries essentially no signal. |
Largest Individual Biotech Insider Buys (by Dollar Value, 90d)
| Symbol | Insider | Title | Shares Bought | $ Value |
|---|---|---|---|---|
| KOD | BAKER BROS. ADVISORS LP | Director | 1.942e+06 | 1.57e+08 |
| MPLT | Catalyst4, Inc. | 10% Owner | 5.609e+06 | 6.539e+07 |
| BRVE | Forbion Growth Opportunities Fund III Cooperatief U.A. | 10% Owner | 3.6e+06 | 6.48e+07 |
| BRVE | Chimovits Erez | — | 1.94e+06 | 3.492e+07 |
| BRVE | ORBIMED ADVISORS LLC | — | 1.94e+06 | 3.492e+07 |
| ETRA | GORDON CARL L | — | 1.333e+06 | 2e+07 |
| ETRA | ORBIMED ADVISORS LLC | — | 1.333e+06 | 2e+07 |
| BRVE | AH Bio Fund IV, L.P. | 10% Owner | 1.1e+06 | 1.98e+07 |
| CBIO | Fairmount Funds Management LLC | — | 8.534e+05 | 1.238e+07 |
| ALMS | AKKARAJU SRINIVAS | Director | 9.867e+05 | 1.073e+07 |
| IMTX | PERCEPTIVE ADVISORS LLC | Director | 8.631e+05 | 7.5e+06 |
| PBLS | RA CAPITAL MANAGEMENT, L.P. | Director | 2.446e+05 | 6.92e+06 |
| APMD | Morningside Venture Investments Ltd | 10% Owner | 3.125e+05 | 5e+06 |
| INBX | Lappe Mark | Chief Executive Officer | 3.5e+04 | 3.644e+06 |
| LTGO | Tananbaum James B. | Director | 1.4e+05 | 2.52e+06 |
| LTGO | Foresite Capital Management V, LLC | — | 1.4e+05 | 2.52e+06 |
| KURA | WILSON TROY EDWARD | President and CEO | 2e+05 | 2.351e+06 |
| INBX | Kayyem Jon Faiz | — | 1.5e+04 | 1.568e+06 |
| BRVE | Murdoch Travis | CEO and President | 8.333e+04 | 1.5e+06 |
| BRVE | Viehbacher Christopher | — | 8.333e+04 | 1.5e+06 |
| COO | Kurzius Lawrence Erik | Director | 2e+04 | 1.088e+06 |
| IONS | Hayden Michael R | — | 2e+04 | 1.059e+06 |
| ABCL | Hayden Michael R | — | 1e+05 | 1.051e+06 |
| EIKN | Column Group IV GP, LP | 10% Owner | 8.92e+04 | 1.031e+06 |
| BRVE | Lubner David Charles | — | 5.556e+04 | 1e+06 |
| RGNX | Ciongoli Gregory Austin | Director | 1.026e+05 | 9.494e+05 |
| RLMD | Shenouda Maged | Chief Financial Officer | 2e+05 | 8.44e+05 |
| COO | Rosebrough Walter M Jr | Director | 1e+04 | 5.416e+05 |
| BRVE | Rickey James Paul | Chief Financial Officer | 2.778e+04 | 5e+05 |
| ASND | BIENAIME JEAN JACQUES | Director | 2,000 | 4.927e+05 |
| ABCL | Booth Andrew | Chief Financial Officer | 3.72e+04 | 3.839e+05 |
| INBX | FORSYTH DOUGLAS | — | 2,500 | 2.866e+05 |
| DMRA | Jarrett Jennifer | Director, President and CEO | 1.25e+04 | 2.529e+05 |
| COO | Keel Paul A | Director | 4,701 | 2.5e+05 |
| NAMS | Davidson Michael H. | Chief Executive Officer | 1e+04 | 2.265e+05 |
| APMD | SEKHRI PAUL J | Director | 1.25e+04 | 2e+05 |
| PODD | McEvoy Ashley | President and CEO | 1,100 | 1.622e+05 |
| MPLT | Cox Troy | Director | 1.562e+04 | 1.487e+05 |
| ABCL | Montalbano John S. | — | 1e+04 | 1.103e+05 |
| INDV | Anderson Woodrow D | Chief Accounting Officer | 3,000 | 1.08e+05 |
| ANNX | Love Douglas | PRESIDENT AND CEO | 2.606e+04 | 9.983e+04 |
| BRVE | Malek David I | — | 4,166 | 7.499e+04 |
| DYN | Posner Brian S | Director | 2,500 | 4e+04 |
| PGEN | AGEE NANCY H | — | 3,411 | 2.466e+04 |
| BRVE | Anderson Michele A. | Chief Development Officer | 1,111 | 2e+04 |
0
Insider conviction in biotech is concentrated in the small-cap, post-IPO cohort
The pattern behind the screen. Insider net buying across US-listed biotech is not evenly spread — it clusters in freshly-listed, clinical-stage names and in specialist crossover funds taking anchor positions. The heaviest readings on a share-of-float basis come from recent IPOs (Braveheart Bio, Scribe Therapeutics, MapLight, Electra), where a small public float mechanically magnifies the percentage and where the buyers are the same venture and crossover funds that underwrote the offering (Forbion, Orbimed, RA Capital, Perceptive, Foresite, Fairmount). That is real money, but it is also the expected behavior of sponsors defending a recent listing — so the float-based ranking should be read as "sponsor alignment," not necessarily as a contrarian tell.
Where the signal is stronger. The higher-quality reads are the management-cluster buys in names that have already de-rated: Kodiak Sciences (Baker Bros. adding to a name that has nearly tripled), Xenon Pharmaceuticals (CEO and CFO buying together after a sharp drawdown), Inhibrx Biosciences (CEO and two directors), Kura Oncology (CEO Troy Wilson's repeated open-market accumulation) and AbCellera (a director buying into a stock that is already among the group's best performers). Buying into strength or buying a coordinated management block after weakness are the two setups historically worth more attention than a lone, small director purchase.
The balance-sheet risk that never goes away. For the smallest names here the insider buy does not remove financing risk — clinical-stage companies with sub-$1B market caps still depend on the capital markets, and insider purchases at the top of the float-based ranking (Dyne, Annexon, Tyra, Damora, Precigen, Pfizer/AstraZeneca) are economically trivial and should be discounted accordingly.
Where it fits in the tape. Health Care has quietly become a leadership block over the past month, with life-science tools, drug-discovery platforms and M&A headlines (Viatris/Pacira, Novartis/Abogen) turning the sector from a funding source back into an accumulation target. Insider buying in biotech at the same time that the sector's relative strength is improving is a constructive combination — but with a heavy Q3 reporting calendar imminent, position sizing around catalysts rather than ahead of them remains the disciplined approach.
Run a version of this yourself
Describe the idea in plain English and Relaxfolio returns a researchable shortlist with the charts, fundamentals, and risks attached.
Educational research tool — not investment advice. A screen is a starting point, not a recommendation.